

# Corporate Medical Policy

## Chromoendoscopy as an Adjunct to Colonoscopy

**File Name:** chromoendoscopy\_as\_an\_adjunct\_to\_colonoscopy  
**Origination:** 7/2012  
**Last Review:** 11/2023

### Description of Procedure or Service

---

Chromoendoscopy refers to the application of dyes or stains during endoscopy to enhance tissue differentiation or characterization. When used with colonoscopy, the intent is to increase the sensitivity of the procedure by facilitating the identification of mucosal abnormalities. There are two types of chromoendoscopy; one involves actual spraying of dyes or stains through the working channel of an endoscope. The other type, known as virtual chromoendoscopy, uses a computer algorithm to simulate different colors of light that result from dye or stain spraying.

#### Background

Colonoscopy, a procedure during which colonic and rectal polyps can be identified and removed, is considered the criterion standard test for colorectal cancer screening and diagnosis of colorectal disease. However, colonoscopy is an imperfect procedure. A recent systematic review and meta-analysis by Zhao et al (2019) pooled findings from more than 15,000 tandem (i.e. back-to-back) colonoscopy studies in 43 publications and found a miss rate of 26% for adenomas, 9% for advanced adenomas, and 27% for serrated polyps. Miss rates were higher for proximal advanced adenomas (14%), serrated polyps (27%), flat adenomas (34%), and in patients at high risk for CC (33%).

Several adjunct endoscopic techniques, including chromoendoscopy, could potentially enhance the sensitivity of colonoscopy. Chromoendoscopy, also known as chromoscopy and chromocolonoscopy, refers to the application of topical stains or dyes during endoscopy in order to enhance tissue differentiation or characterization and facilitate the identification of mucosal abnormalities. Chromoendoscopy may be particularly useful for detecting flat or depressed lesions. Standard colonoscopy uses white light to view the colon. In chromoendoscopy, stains are applied, resulting in color highlighting of areas of surface morphology of epithelial tissue. The dyes or stains are applied via a spray catheter that is inserted down the working channel of the endoscope. Chromoendoscopy can be used in the whole colon (pancolonic chromoendoscopy) on an untargeted basis or can be directed to a specific lesion or lesions (targeted chromoendoscopy). Chromoendoscopy differs from endoscopic tattooing in that the former uses transient stains, whereas tattooing involves the use of a long-lasting pigment for future localization of lesions.

Stains and dyes used in chromoendoscopy can be placed in the following categories:

- **Absorptive:** These stains are preferentially absorbed by certain types of epithelial cells.
- **Contrast:** These stains seep through mucosal crevices and highlight surface topography.
- **Reactive:** These stains undergo chemical reactions when in contact with specific cellular constituents, which results in a color change.

Reactive stains are primarily used to identify gastric abnormalities and are not used with colonoscopy. Indigo carmine, a contrast stain, is one of the most commonly used stains with colonoscopy to enhance the detection of colorectal neoplasms. Several absorptive stains are also used with colonoscopy. Methylene blue is widely used; it stains the normal absorptive epithelium of the small intestine and colon, and has been used to detect colonic neoplasia and to aid in the detection of intraepithelial neoplasia in individuals with chronic ulcerative colitis. In addition, crystal violet (also

# Chromoendoscopy as an Adjunct to Colonoscopy

known as gentian violet), stains cell nuclei and has been applied in the colon to enhance visualization of pit patterns (i.e. superficial mucosal detail).

Potential applications of chromoendoscopy as an alternative to standard colonoscopy include:

- Diagnosis of colorectal neoplasia in symptomatic patients at increased risk of colorectal cancer due to family history of colorectal cancer, personal history of adenomas, etc.
- Identification of mucosal abnormalities for targeted biopsy as an alternative to multiple random biopsies in patients with inflammatory bowel disease (IBD)
- Screening the general population for colorectal cancer

The equipment used in regular chromoendoscopy is widely available. Several authors of review articles and technology assessments have stated that, although the techniques are simple, the procedure, e.g. concentration of dye and amount of dye sprayed, is variable and classification of mucosal staining patterns for identifying specific conditions is not standardized.

Virtual chromoendoscopy (also called electronic chromoendoscopy) involves imaging enhancements with endoscopy systems that could potentially be an alternative to dye spraying. One system is the Fujinon Intelligent Color Enhancement feature (Fujinon, Inc.). This technology uses post-processing computer algorithms to modify the light reflected from the mucosa from conventional white light to various other wavelengths.

## Regulatory Status

In 2014, the Fujifilm EPX-4440HD Digital Video Processor with Fujinon Intelligent Color Enhancement (FICE®) and Light Source (FujiFilm) was cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process. FDA documents state that FICE® can be used to supplement white-light endoscopy but is not intended to replace histopathologic sampling as a means of diagnosis.

In 2012, i-SCAN™ (Pentax), used for virtual chromoendoscopy, was cleared for marketing by FDA through the 510(k) process. This is a digital image enhancement technology is part of the Pentax EPK-i5010 Video Processor. The i-SCAN™ has several modes that digitally enhance images in real-time during endoscopy. FDA documents state that i-SCAN™ is intended as an adjunct following white-light endoscopy and is not intended to replace histopathologic analysis.

No dye or stain product has been specifically approved by the FDA for use in chromoendoscopy.

## Related Policies

Confocal Laser Endomicroscopy

***\*\*\*Note: This Medical Policy is complex and technical. For questions concerning the technical language and/or specific clinical indications for its use, please consult your physician.***

---

## Policy

**Chromoendoscopy and virtual chromoendoscopy are considered investigational as an adjunct to diagnostic or surveillance colonoscopy. BCBSNC does not provide coverage for investigational services or procedures.**

---

## Benefits Application

This medical policy relates only to the services or supplies described herein. Please refer to the Member's Benefit Booklet for availability of benefits. Member's benefits may vary according to benefit design; therefore member benefit language should be reviewed before applying the terms of this medical policy.

# Chromoendoscopy as an Adjunct to Colonoscopy

## **When Chromoendoscopy as an Adjunct to Colonoscopy is covered**

---

Not applicable.

## **When Chromoendoscopy as an Adjunct to Colonoscopy is not covered**

---

Chromoendoscopy and virtual chromoendoscopy are considered investigational as an adjunct to diagnostic or surveillance colonoscopy.

## **Policy Guidelines**

---

The evidence for chromoendoscopy in patients who have an average risk of colorectal cancer (CC) undergoing colonoscopy includes randomized controlled trials (RCTs) and a meta-analysis of these RCTs. Relevant outcomes are overall survival (OS), disease-specific survival (DSS), test validity, and change in disease status. The meta-analysis demonstrated that dye-based chromoendoscopy increased the adenoma detection rate and adenomas per colonoscopy in patients at average or increased risk of CC compared to standard or high-definition white light colonoscopy. However, limitations included unclear indication of colonoscopy in the studies (which included patients with screening and surveillance), and some heterogeneity in mean adenomas per patient. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

The evidence for chromoendoscopy in patients who have an increased risk of CC undergoing colonoscopy includes multiple RCTs and systematic reviews. Relevant outcomes are OS, DSS, test validity, and change in disease status. A Cochrane systematic review of trials comparing chromoendoscopy with standard colonoscopy in high-risk patients (but excluding those with inflammatory bowel disease [IBD]) found significantly higher rates of adenoma detection and rates of 3 or more adenomas with chromoendoscopy compared with standard colonoscopy. The evidence for detecting larger polyps, defined as greater than 5 mm or greater than 10 mm, is less robust. While 1 study reported a significantly higher detection rate for polyps greater than 5 mm, no studies reported increased detection of polyps greater than 10 mm. A recent RCT and systematic review involving patients with Lynch syndrome also found equivocal results. Results from the RCT showed similar neoplasia detection rates with chromoendoscopy and conventional white-light colonoscopy, while the systematic review concluded that chromoendoscopy is associated with significantly improved detection of certain lesions; however, the odds of having an adenoma detected were not significantly different between the modalities. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

The evidence for chromoendoscopy in patients who have inflammatory bowel disease undergoing colonoscopy includes meta-analyses and recent RCT. Relevant outcomes are OS, DSS, test validity, and change in disease status. Several meta-analyses found a statistically significant higher yield of chromoendoscopy over standard white-light colonoscopy for detecting dysplasia. The evidence supported improved polyp detection rates, with chromoendoscopy; however the studies had limitations such as lack of information regarding the timing of the screening modalities. A recent RCT found increased detection of dysplasia with chromoendoscopy compared to white-light endoscopy, although the benefit was only observed in a subgroup analysis in the second half of the study follow-up period. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have an average risk of CC who receive virtual chromoendoscopy, the evidence includes several RCTs and systematic reviews. Relevant outcomes are OS, DSS, test validity, and change in disease status. The available RCTs have not found that virtual chromoendoscopy improves the detection of clinically important polyps compared with standard white-light colonoscopy. Moreover, there is a lack of studies assessing the impact of virtual chromoendoscopy on CC incidence

# Chromoendoscopy as an Adjunct to Colonoscopy

and mortality rates compared with standard colonoscopy. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have an increased risk of CC who receive virtual chromoendoscopy, the evidence includes RCTs. Relevant outcomes are OS, DSS, test validity, and change in disease status. The available RCTs have not found that virtual chromoendoscopy improves the detection of clinically important polyps compared with standard white-light colonoscopy. Moreover, there is a lack of studies assessing the impact of virtual chromoendoscopy on CC incidence and mortality rates compared with standard colonoscopy. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have IBD who receive virtual chromoendoscopy, the evidence includes 2 meta-analyses and 2 RCTs. Relevant outcomes are OS, DSS, test validity, and change in disease status. One meta-analysis showed superiority of virtual chromoendoscopy over high-definition white light colonoscopy for dysplasia per biopsy, and ranked virtual chromoendoscopy as the best option for screening among the different modalities in comparison. The second meta-analysis found no difference between dye-based chromoendoscopy and virtual chromoendoscopy for dysplasia detection. One RCT found a significantly greater likelihood that virtual chromoendoscopy would correctly identify the extent of disease inflammation than standard colonoscopy but no significant difference in the likelihood of identifying disease activity. The other RCT found that there was no significant difference in the detection of neoplasia between high definition white light versus high-definition virtual chromoendoscopy in patients with long-standing IBD. There is a lack of studies assessing the impact of virtual chromoendoscopy on CC incidence and mortality rates compared with standard colonoscopy. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

## **Billing/Coding/Physician Documentation Information**

---

This policy may apply to the following codes. Inclusion of a code in this section does not guarantee that it will be reimbursed. For further information on reimbursement guidelines, please see Administrative Policies on the Blue Cross Blue Shield of North Carolina web site at [www.bcbsnc.com](http://www.bcbsnc.com). They are listed in the Category Search on the Medical Policy search page.

*Applicable codes: No specific code.*

There is no specific code for chromoendoscopy. The additional work of the chromoendoscopy would probably be reported with the unlisted CPT code 44799.

BCBSNC may request medical records for determination of medical necessity. When medical records are requested, letters of support and/or explanation are often useful, but are not sufficient documentation unless all specific information needed to make a medical necessity determination is included.

## **Scientific Background and Reference Sources**

---

BCBSA Medical Policy Reference Manual [Electronic Version]. 2.01.84, 3/8/12

BCBSA Medical Policy Reference Manual [Electronic Version]. 2.01.84, 3/14/13

Specialty Matched Consultant Advisory Panel 10/2013

BCBSA Medical Policy Reference Manual [Electronic Version]. 2.01.84, 3/13/14

Specialty Matched Consultant Advisory Panel 11/2014

# Chromoendoscopy as an Adjunct to Colonoscopy

Senior Medical Director review 12/2014

BCBSA Medical Policy Reference Manual [Electronic Version]. 2.01.84, 3/12/15

Specialty Matched Consultant Advisory Panel 11/2015

Medical Director review 11/2015

BCBSA Medical Policy Reference Manual [Electronic Version]. 2.01.84, 11/12/15

Specialty Matched Consultant Advisory Panel 11/2016

Medical Director review 11/2016

BCBSA Medical Policy Reference Manual [Electronic Version]. 2.01.84, 11/2016

Specialty Matched Consultant Advisory Panel 11/2017

Medical Director review 11/2017

BCBSA Medical Policy Reference Manual [Electronic Version]. 2.01.84, 11/2017

Specialty Matched Consultant Advisory Panel 11/2018

Medical Director review 11/2018

BCBSA Medical Policy Reference Manual [Electronic Version]. 2.01.84, 11/2018

Specialty Matched Consultant Advisory Panel 11/2019

Medical Director review 11/2019

BCBSA Medical Policy Reference Manual [Electronic Version]. 2.01.84, 11/2019

Specialty Matched Consultant Advisory Panel 11/2020

Medical Director review 11/2020

BCBSA Medical Policy Reference Manual [Electronic Version]. 2.01.84, 12/2020

Specialty Matched Consultant Advisory Panel 11/2021

Medical Director review 11/2021

Specialty Matched Consultant Advisory Panel 11/2022

Medical Director review 11/2022

Zhao S, Wang S, Pan P, et al. Magnitude, Risk Factors, and Factors Associated With Adenoma Miss Rate of Tandem Colonoscopy: A Systematic Review and Meta-analysis. *Gastroenterology*. May 2019; 156(6): 1661-1674.e11. PMID 30738046

U.S. Food & Drug Administration. 510(k) Premarket Notification (K140149). 2014;  
<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K140149>

# Chromoendoscopy as an Adjunct to Colonoscopy

Food and Drug Administration (FDA). 510(k) Summary: Pentax EPK-i5010 Video Processor. 2013; [http://www.accessdata.fda.gov/cdrh\\_docs/pdf12/K122470.pdf](http://www.accessdata.fda.gov/cdrh_docs/pdf12/K122470.pdf)

Antonelli G, Correale L, Spadaccini M, et al. Dye-based chromoendoscopy for the detection of colorectal neoplasia: meta-analysis of randomized controlled trials. *Gastrointest Endosc. Sep 2022; 96(3): 411-422. PMID 35588768*

Har-Noy O, Yung DE, Koulaouzidis A, et al. Chromoendoscopy or white light endoscopy for neoplasia detection in Lynch syndrome, a meta-analysis. *Dig Liver Dis. Nov 2019; 51(11): 1515-1521. PMID 31526715*

Brown SR, Baraza W. Chromoscopy versus conventional endoscopy for the detection of polyps in the colon and rectum. *Cochrane Database Syst Rev. Oct 06 2010; (10): CD006439. PMID 20927746*

Specialty Matched Consultant Advisory Panel 11/2023

Medical Director review 11/2023

## Policy Implementation/Update Information

---

- 07/24/12 New policy issued. Chromoendoscopy and virtual chromoendoscopy are considered investigational as an adjunct to diagnostic or surveillance colonoscopy. Notification given 7/24/12 for policy effective date of 10/30/12. (sk)
- 5/28/13 Related policy added. Reference added. No change to policy statement. (sk)
- 11/12/13 Specialty Matched Consultant Advisory Panel review 10/16/2013. No change to policy statement. (sk)
- 5/27/14 Reference added. No change to Policy statement. (sk)
- 1/13/15 References update. Specialty Matched Consultant Advisory Panel review 11/2014. Senior Medical Director review 12/2014. No change to Policy statement. (td)
- 4/28/15 References updated. Description section revised. Policy Statement remains unchanged. (td)
- 12/30/15 References update. Specialty Matched Consultant Advisory Panel review 11/18/2015. Medical Director review 11/2015. Policy Statement remains unchanged. (td)
- 4/29/16 Description section revised. Policy Guidelines revised extensively. References updated. (td)
- 12/30/16 References updated. Specialty Matched Consultant Advisory Panel review 11/2016. Medical Director review 11/2016. (jd)
- 12/15/17 References updated. Specialty Matched Consultant Advisory Panel 11/2017. Medical Director review 11/2017. (jd)
- 12/14/18 Minor revisions. References updated. Specialty Matched Consultant Advisory Panel 11/2018. Medical Director review 11/2018. (jd)
- 12/31/19 References updated. Specialty Matched Consultant Advisory Panel 11/2019. Medical Director review 11/2019. (jd)

# Chromoendoscopy as an Adjunct to Colonoscopy

- 12/8/20 References updated. Specialty Matched Consultant Advisory Panel 11/2020. Medical Director review 11/2020. (jd)
- 11/30/21 Specialty Matched Consultant Advisory Panel 11/2021. Medical Director review 11/2021. (jd)
- 11/29/22 References updated. Specialty Matched Consultant Advisory Panel 11/2022. Medical Director review 11/2022. (tm)
- 12/29/23 Description, Policy Guidelines and References updated. Specialty Matched Consultant Advisory Panel 11/2023. Medical Director review 11/2023. (tm)

---

Medical policy is not an authorization, certification, explanation of benefits or a contract. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the group contract and subscriber certificate that is in effect at the time services are rendered. This document is solely provided for informational purposes only and is based on research of current medical literature and review of common medical practices in the treatment and diagnosis of disease. Medical practices and knowledge are constantly changing and BCBSNC reserves the right to review and revise its medical policies periodically.